scholarly journals In Vivo Assessment of Antioxidants and Antihyperglycemic Effect of Barleria cristata leaves in Streptozotocin- Induced Diabetic Rats

2014 ◽  
Vol 2 (4) ◽  
pp. 437-445 ◽  
Author(s):  
Narmadha Rajasekaran ◽  
Gomathi Duraisamy ◽  
Kalaiselvi Manokaran ◽  
Devaki Kanakasapathi

Objective: Many new bioactive drugs isolated from plants having hypoglycaemic effects showed anti diabetic activity equal and sometimes even more potent than known oral hypoglycaemic agents. In this present study, designed to evaluate antihyperglycermic and antioxidants effect on ethanolic leaf extracts Barleria cristata (EtBc) in streptozotocin-induced diabetic rats at dose level 400mg/kg body weight for the treatment of 45 days. Method and materials: The experimental rats were randomly divided into five groups as a control, streptozotocin induced with diabetes (45mg/kg bw) without any treatment, treated with standard drug glibenclamide (1.25 mg/kg bw), EtBc (400 mg/kg bw) in diabetic induced rats and treated with EtBc alone without diabetic rats. At the end of 45th day animals were sacrificed, collect the serum, liver, kidney and pancreas for estimate the glucose, insulin, C-peptide, glycosylated hemoglobin, hemoglobin in serum, protein, enzymatic and nonenzymatic antioxidants and lipid peroxidation in tissues. Results: After the administration of EtBc, blood glucose levels were showed significantly reduction (P<0.05) in diabetic rats and it has been observed alternation occured in body and organ weight and it was also normalized the serum level of glycemic profile like insulin, C-peptide, total hemoglobin and glycosylated hemoglobin levels similar to that of control rats. Antioxidants enzymes were return to back their levels as control in different tissues when compared to diabetic rats and also observed no significance difference between control and EtBc alone group rats at the end of 45th day. Therefore it was suggested that Barleria cristata may act by potentiation of pancreatic secretion of insulin or increasing glucose uptake by muscle cells. Conclusion: In this study, suggested the efficacy of Barleria cristata proved the maintenance of glucose homeostasis and may be used as a therapeutic agent in the management of diabetes mellitus.DOI: http://dx.doi.org/10.3126/ijasbt.v2i4.11219 Int J Appl Sci Biotechnol, Vol. 2(4): 437-445 

Author(s):  
Marcella Tari Joshua ◽  
Edna O. Wachuku ◽  
N. Boisa ◽  
Nsirim Nduka

Aim: The aim of this study therefore was to evaluate the antidiabetic potentials of Morus mesozygia Linn. Stapf., Leaf extrcts in Streptozotocin-Induced Diabetic Rats. Study Design:  The study is an experimental case-controlled study. Place and Duration of Study: This study was carried out at the Biochemistry Research Laboratory, University of Port Harcourt, Rivers State, Nigeria, between June 2018-April 2019. Methodology: A total of 65 male albino rats that weighed between 150g to 200g were used for this research study. Three different extracted solvents; aqueous, ethanolic and methanolic leaves extracts were administered to different groups of the rats. The male albino rats for this study were induced with a single dose of 40mg/kg b.wt, intraperitoneally of streptozotocin in 0.1M of citrate buffer, pH 4.5. The diabetic male rats were those whose fasting blood glucose (FBG) was from 250 mg/dl or 13 mmol/L and above. Results: The results showed that there were significant decreases (p<0.05) in, FBG, increased insulin and increased C-peptide and increased HOMA-IR concentration of induced diabetic male rats treated orally with 400 mg/kg of MMLS., when compared with the values of the diabetic male rats in treated orally with 200 mg/kg of MMLS., and non-significant decrease(p<0.05) in FBG, HOMA-IR increased insulin, increased C-peptide concentrations in the diabetic male rats treated orally for 30 days with 400 mg/kg in dose of methanolic leaves extracts of MMLS., in the group treated with 400 mg/kg methanol, when compared to the concentration of diabetic male in treated orally for 30 days with 200 mg/kg of methanolic leaves extracts of MMLS. Compared likewise with that treated with 100mg/kg of metformin standard drug. There were also significant decrease (p<0.05) in FBG, HOMA-IR, C-peptide and increased insulin concentrations in diabetic male rats treated with 200 mg/kg in dose of ethanolic and methanolic leaves extracts of MMLS., when compared with the values in the diabetic male rats treated orally with 400 mg/kg in dose of ethanolic and methanolic leaves extracts of MMLS., compared with values of diabetic male rats treated orally with 100mg/kg in dose of metformin standard drugs compared with the controls. Conclusion: From the findings of this study, we conclude that streptozotocin increased FBG levels, while the Methanolic, ethanolic and aqueous extracts of Morus mesozygia Linn. S improved FBG, C-peptide, insulin and HOMA levels in a dose-dependent manner, with the methanolic extract having the best ameliorative effect, probably due to its more phytochemical composition.


Author(s):  
Zuneera Akram ◽  
Aisha Noreen ◽  
Muzammil Hussain ◽  
Maryam Inayat ◽  
Sobia Akhter ◽  
...  

Diabetes mellitus has high global prevalence and occurrence and is considered to bean endocrinological and/or metabolic disorder. Conventional drug treatment is costly and has toxic side effects, although it is successful in treating diabetes mellitus. If effective and less toxic, herbal medicine will thus include alternative therapy. This research has been designed to investigate the role of Grewia asiatica extract in the control of diabetes in male albino rats with Streptozotocin mediated type 2 diabetes. Grewia asiatica fruit extract at a dose of 200mg/kg was given to Streptozotocin mediated type II DM Rats. A known anti-diabetic drug, Glibenclamide has been used as a standard drug. The method of the research was to monitor the effect of Grewia asiatica on the blood glucose level of Rats. In this study, Rats were split into four categories i.e. Control, Streptozotocin treated, Streptozotocin + Glibenclamide treated and Streptozotocin +Grewia asiatica extract-treated group.  Grewia asiatica fruit extract significantly improve the blood glucose levels as compared to the standard drug Glibenclamide in Streptozotocin mediated diabetic group. Conclusion: It was concluded that Grewia asiatica may be used in the treatment of diabetes or decreasing the elevated level of blood sugar.


2021 ◽  
Vol 12 (6) ◽  
pp. 7321-7341

The in vitro antidiabetic and antioxidant potential of Punica granatum, Eriobotrya japonica, and Musa acuminata leaves were evaluated using normal and streptozocin (STZ) induced diabetic rats. Experimental diabetes was induced into Wister rats using streptozocin (40 mg/kg), injected intraperitoneal (IP). Orally crude methanolic leaves extracts were administered in streptozocin induced diabetic rats (n=6) along with the fractions (chloroform, ethyl acetate, and aqueous) of P. granatum, E. japonica, and M. acuminata (50 mg/kg) along with standard drug glimepiride (2 mg/kg) for 28 days. Rats' blood samples were tested for blood glucose using glucose oxidase reactive strips and glucometer. Glucose was administered to nondiabetic control rats. The rats were also treated with glimepiride and leaves extracts of P. granatum, E. japonica, and M. acuminata to check the oral glucose tolerance (OGTT). Blood glucose levels were checked at 0, 30, 60, 120 minutes intervals after drug administration. The effect of various fractions of leaf extracts on the bodyweight of rats was also studied. Data obtained was evaluated by two-way Analysis of Variance (ANOVA) and expressed as standard deviation. Leaves extracts exhibit significant antidiabetic and antioxidant properties. These medicinal plants with antioxidant and antidiabetic properties could be an economical source of local medicine for diabetes.


Author(s):  
Ganga Rajum ◽  
Hema Sundar Reddy T ◽  
Hema Sundar Reddy T

  Objective: The present study was aimed to evaluate antihyperglycemic and antihyperlipidemic activities of methanolic extract of Aristolochia bracteolata (MEAB) against dexamethasone-induced diabetic rat model.Methods: Methanolic extract was prepared by soxhlet extraction and was evaluated for antihyperglycemic and antihyperlipidemic activity using dexamethasone-induced model. The MEAB was administered orally at a dose of 200 and 400 mg/kg body weight glibenclamide was used as standard drug. On 0th and 11th day, blood was collected by retro-orbit plexus.Results: In this model blood glucose levels were determined on 0th and 11th days and MEAB significantly reduced the blood glucose levels in diabetic rats. The effect of MEAB on serum lipid profile such as total cholesterol (TC), triglycerides (TGs), low-density lipoprotein (LDL), very LDL (VLDL), and high-density lipoprotein (HDL) was also measured on the 11th day in the diabetic rats. Significant reduction in TC, TGs, LDL, and VLDL levels and improvement in HDL level were observed in diabetic rats.Conclusion: From the results, it was found that the MEAB possess antihyperglycemic and antihyperlipidemic activities.


2008 ◽  
Vol 5 (4) ◽  
pp. 421-428 ◽  
Author(s):  
Omar Said ◽  
Stephen Fulder ◽  
Khaled Khalil ◽  
Hassan Azaizeh ◽  
Eli Kassis ◽  
...  

Safety and anti-diabetic effects of Glucolevel, a mixture of dry extract of leaves of theJuglans regiaL,Olea europeaL,Urtica dioicaL andAtriplex halimusL were evaluated usingin vivoandin vitrotest systems. No sign of toxic effects (using LDH assay) were seen in cultured human fibroblasts treated with increasing concentrations of Glucolevel. Similar observations were seenin vivostudies using rats (LD50: 25 g/kg). Anti-diabetic effects were evidenced by the augmentation of glucose uptake by yeast cells (2-folds higher) and by inhibition of glucose intestinal absorption (∼49%) in a rat gut-segment. Furthermore, treatment with Glucolevel of Streptozotocin-induced diabetic rats for 2–3 weeks showed a significant reduction in glucose levels [above 400 ± 50 mg/dl to 210 ± 22 mg/dl (P< 0.001)] and significantly improved sugar uptake during the glucose tolerance test, compared with positive control. In addition, glucose levels were tested in sixteen human volunteers, with the recent onset of type 2 diabetes mellitus, who received Glucolevel tablets 1 × 3 daily for a period of 4 weeks. Within the first week of Glucolevel consumption, baseline glucose levels were significantly reduced from 290 ± 40 to 210 ± 20 mg/dl. At baseline, a subgroup of eleven of these subjects had glucose levels below 300 mg% and the other subgroup had levels ≥ 300 mg%. Clinically acceptable glucose levels were achieved during the 2–3 weeks of therapy in the former subgroup and during the 4th week of therapy in the latter subgroup. No side effect was reported. In addition, a significant reduction in hemoglobin A1C values (8.2 ± 1.03 to 6.9 ± 0.94) was found in six patients treated with Glucolevel. Results demonstrate safety, tolerability and efficacy of herbal combinations of four plants that seem to act differently but synergistically to regulate glucose-homeostasis.


2016 ◽  
Vol 231 (1) ◽  
pp. 97-108 ◽  
Author(s):  
Mahendra Prasad Bhatt ◽  
Yeon-Ju Lee ◽  
Se-Hui Jung ◽  
Yong Ho Kim ◽  
Jong Yun Hwang ◽  
...  

C-peptide exerts protective effects against diabetic complications; however, its role in inhibiting hyperglycemic memory (HGM) has not been elucidated. We investigated the beneficial effect of C-peptide on HGM-induced vascular damage in vitro and in vivo using human umbilical vein endothelial cells and diabetic mice. HGM induced apoptosis by persistent generation of intracellular ROS and sustained formation of ONOO− and nitrotyrosine. These HGM-induced intracellular events were normalized by treatment with C-peptide, but not insulin, in endothelial cells. C-peptide also inhibited persistent upregulation of p53 and activation of mitochondrial adaptor p66shc after glucose normalization. Further, C-peptide replacement therapy prevented persistent generation of ROS and ONOO− in the aorta of diabetic mice whose glucose levels were normalized by the administration of insulin. C-peptide, but not insulin, also prevented HGM-induced endothelial apoptosis in the murine diabetic aorta. This study highlights a promising role for C-peptide in preventing HGM-induced intracellular events and diabetic vascular damage.


2018 ◽  
Vol 27 (8) ◽  
pp. 1289-1293 ◽  
Author(s):  
Anaïs Schaschkow ◽  
Séverine Sigrist ◽  
Carole Mura ◽  
Caroline Dissaux ◽  
Karim Bouzakri ◽  
...  

Following the tremendous development of hydrogels for cell therapy, there is now a growing need for surgical techniques to validate in vivo scaffold benefits for islet transplantation. Therefore, we propose a newly designed surgical procedure involving the injection of hydrogel-embedded pancreatic islets in the omentum, which is considered a favorable environment for cell survival and function. Our technique, called h-Omental Matrix Islet filliNG (hOMING) was designed to test the benefits of hydrogel on islet survival and function in vivo. Islets were implanted in the omentum of diabetic rats using the hOMING technique and alginate as an islet carrier. Blood glucose and C-peptide levels were recorded to assess graft function. After 2 months, grafts were explanted and studied using insulin and vessel staining. All rats that underwent hOMING exhibited graft function characterized by a glycemia decrease and a C-peptidemia increase ( P < 0.001 compared with preoperative levels). Furthermore, hOMING appeared to preserve islet morphology and insulin content and allowed the proper revascularization of grafted islets. The results suggest that hOMING is a viable and promising approach to test in vivo the benefits of hydrogel administration for islet transplantation into the omental tissue.


2006 ◽  
Vol 84 (6) ◽  
pp. 647-654 ◽  
Author(s):  
Sameer Mohammad ◽  
Asia Taha ◽  
Kamal Akhtar ◽  
R.N.K. Bamezai ◽  
Najma Zaheer Baquer

Plasma glucose levels are maintained by a precise balance between glucose production and its use. Liver pyruvate kinase (PK) and phosphoenolpyruvate carboxykinase (PEPCK), 2 key enzymes of glycolysis and gluconeogenesis, respectively, play a crucial role in this glucose homeostasis along with skeletal muscle glucose transporter (GLUT4). In the diabetic state, this balance is disturbed owing to the absence of insulin, the principal factor controlling this regulation. In the present study, alloxan-diabetic animals having high glucose levels of more than 300 mmol/L have been taken and the administration of Trigonella seed powder (TSP) to the diabetic animals was assessed for its effect on the expression of PK and PEPCK in liver and GLUT4 distribution in skeletal muscle of alloxan-diabetic rats. TSP treatment to the diabetic animals resulted in a marked decrease in the plasma glucose levels. Trigonella treatment partially restored the altered expression of PK and PEPCK. TSP treatment also corrected the alterations in the distribution of GLUT4 in the skeletal muscle.


2019 ◽  
Vol 35 (4) ◽  
pp. 1398-1406
Author(s):  
Sheryl Joyce B. Grijaldo ◽  
Noel S. Quiming ◽  
Marilou G. Nicolas ◽  
Michael Russelle S. Alvarez

Diabetes mellitus, a complex chronic disease that is associated with hyperglycemia (high blood sugar) affects millions of people worldwide. This study evaluated the hypoglycemic activities of male and female Antidesma bunius, commonly known as currant tree or bignay, extracts in alloxan-treated ICR mice. In addition, the effects of the treatments on blood urea nitrogen (BUN) and creatinine levels were determined. Phytochemical screening using standard protocol was performed. Plant extracts (500 mg/kg) were administered orally via gavage for 14 days and fasting blood glucose (FBG) levels were monitored prior to alloxan-induction on the day of alloxan-induction, and on the 3rd, 7th and 14th days of treatment. Sera were collected on the 14th day to measure the BUN and creatinine levels. Phytochemical screening was performed using standard TLC spray tests. All extracts were found to significantly lower FBG levels compared to the positive (glibenclamide 10 mg/kg) and negative (distilled water) controls (One-way ANOVA, p-value<0.0001). The most active extract, aqueous male A. bunius extract, significantly lowered FBG levels by as much as 61.26±17.89% after the 14th day (paired t-test, p-value = 0.0211). Both BUN and creatinine values were found to be significantly different in the treated mice compared to the controls (One-way ANOVA, p-value = 0.0005 and 0.000479, respectively). The BUN level of all mice was still within normal range, unlike with the creatinine level where only the female and male aqueous A. bunius and female ethanolic A. bunius extracts were within normal range. Phytochemical screening showed the presence of saponins, tannins, and polyphenols, phlobatannins, steroids and terpenoids. This study demonstrates the potential of male and female A. bunius leaf extracts to reduce fasting blood glucose levels. Additional work, pertaining to the identification of possible bioactive compounds and establishing the mechanisms thereof, could be performed.


Sign in / Sign up

Export Citation Format

Share Document